Author:
Lydon Nicholas B,Druker Brian J
Subject
Cancer Research,Oncology,Hematology
Reference83 articles.
1. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia;Druker;J. Clin. Invest.,2000
2. Bcr-Abl inhibition as a modality of CML therapeutics;Buchdunger;Biochim. Biophys. Acta,2001
3. STI571: a paradigm of new agents for cancer therapeutics;Mauro;J. Clin. Oncol.,2002
4. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer;O’Dwyer;Curr. Cancer Drug Targets,2001
5. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative;Buchdunger;Cancer Res.,1996
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献